Feeding Behavior and Energy Regulation

Fundamentals of Homeostasis and Feeding Behavior

  • Homeostasis: This is defined as the physiological process that maintains the internal environment of the body within a narrow, specific range. It ensures stability in response to external changes.

  • The Hypothalamus: Often referred to as the "master regulator" of homeostasis, the hypothalamus plays a critical role in energy balance and regulation. An example of its regulatory function is feeding behavior.

  • Satiety: This refers to the internal feeling of fulfillment or satisfaction following food consumption.     * Satiety Signals: These are "anorexigenic," meaning they inhibit eating behavior.

  • Hunger: This refers to the internal state of an animal or human that motivates the seeking of food.     * Hunger Signals: These are "orexigenic," meaning they promote eating behavior.

  • Brain Integration: The brain integrates peripheral signals (such as insulin and glucose levels from the blood) with central signals from within the brain itself to decide whether to initiate or terminate eating.

Basal Metabolism and Energy Expenditure

  • Basal Metabolism: This is defined as the energy expended for heat production, the maintenance of membrane potentials across various cells, and other essential life-sustaining biological processes.

  • Metabolic Adjustments: Energy expenditure is not static; it is adjusted in response to nutritional intake.     * Dietary Response: At the onset of a diet (a period of less nutrition), the Basal Metabolic Rate (BMR) will fall. This is a survival mechanism intended to prevent weight loss during times of scarcity.

  • Case Study: The Biggest Loser (Season 8): Participants from season 8 of the television show The Biggest Loser regained a significant amount of weight over the six years following the competition.     * Metabolic Suppression: The dramatic weight loss achieved during the show prompted a strong metabolic suppression. This suppression persisted and actually increased over the six-year follow-up period, making weight maintenance extremely difficult for the contestants.

Short-Term and Long-Term Energy Storage

  • The Need for Fuel Storage: The body requires fuel between meals and during times of sudden increased demand, such as the "fight or flight" response.

  • Glucose: This is a simple sugar and the primary energy source for both the body and the brain.

  • Glycogen: A complex carbohydrate used for short-term energy storage, primarily located in the liver and muscles.

  • Glycogenesis: The metabolic process of converting glucose into glycogen for storage. This process is driven by the hormone insulin.

  • Insulin (Primary Role): A pancreatic hormone that regulates the conversion of glucose into glycogen for short-term storage.

  • Glycogenolysis: The metabolic process of converting stored glycogen back into glucose for immediate use.

  • Glucagon: A pancreatic hormone that regulates the conversion of glycogen back into glucose when blood sugar is low.

  • Lipids: These are fats deposited in adipose tissue for longer-term energy storage.

  • Gluconeogenesis: The metabolic process of converting fats and proteins into glucose and ketones (alternative fuel forms).

  • Alternative Fuel Usage: In the absence of glucose, the body can utilize fatty acids for energy. However, the brain is highly specialized and can only use glucose for energy.

Insulin Dynamics and Diabetes

  • Insulin’s Second Role: Beyond storage, insulin enables the body's cells to use glucose. Glucose transporters span the cell membrane and interact with insulin to facilitate the entry of glucose into the cell.

  • Brain and Insulin: Unlike the rest of the body, brain cells do not require insulin to utilize glucose.

  • Diabetes Mellitus: A condition caused by a lack of proper insulin signaling.     * Type 1: The pancreas stops producing insulin entirely.     * Type II: The body exhibits reduced sensitivity to insulin.

  • Blood Sugar Terms:     * Hyperglycemic: Having too much glucose in the blood.     * Hypoglycemic: Having too little glucose in the blood.

The Dual Center Hypothesis and the Arcuate Nucleus

  • Dual-Center Hypothesis: This theory proposes two distinct appetite centers located within the hypothalamus:     * Ventromedial Hypothalamus (VMH): Identified as the satiety center. It signals when you are full. Lesions to the VMH result in overeating (hyperphagia).     * Lateral Hypothalamus (LH): Identified as the hunger center. It signals when you are hungry. Lesions to the LH result in reduced eating (aphagia).

  • Arcuate Nucleus: Another critical appetite center in the hypothalamus. Its activity is governed by feeding-related hormones released from the periphery (the body).

  • fMRI Evidence: Functional Magnetic Resonance Imaging (fMRI) shows that the hypothalamus is active when hungry individuals are administered glucose or when they are shown pictures of food.

Hormonal Regulation of Appetite

  • Leptin: A hormone released by fat cells (adipocytes).     * Role: Regulates body mass by acting on hypothalamic neurons to decrease appetite and increase energy expenditure. It provides the brain with information regarding long-term energy reserves.     * Genetic Studies: Mice with two copies of the obese gene (ob/obob/ob, defective leptin genes) or the diabetes gene (db/dbdb/db, defective leptin receptor genes) become morbidly obese. Treatment of ob/obob/ob mice with leptin reduces their obesity.

  • Insulin: Secreted by the pancreas. Levels rise in anticipation of or during the presence of glucose. It acts as a short-term satiety signal.

  • Ghrelin: A hormone produced by the stomach and secreted into the bloodstream.     * Role: Levels rise during fasting and fall immediately after a meal. It serves as a short-term hunger (orexigenic) signal.

  • Peptide YY (PYY): A hormone produced by the intestines and secreted into the bloodstream.     * Role: Levels are low before eating but rise rapidly after a meal. It serves as a short-term satiety (anorexigenic) signal.

Neural Circuitry of Appetite Control

  • Anorectic Pathways (Satiety): High adiposity and high leptin levels activate neurons in the arcuate nucleus that release POMC (proopiomelanocortin) and CART (cocaine-and-amphetamine-related transcript) peptides.     * These POMC/CART neurons stimulate the lateral hypothalamus to diminish appetite and increase metabolism.

  • Orexigenic Pathways (Hunger): Activation of arcuate neurons that release NPY (neuropeptide Y) and AgRP (agouti-related peptide).     * These neurons inhibit POMC/CART neurons, which in turn stimulates the lateral hypothalamus to increase appetite and reduce metabolism.

  • Hormonal Interactions with Circuitry:     * Leptin: Activates POMC/CART neurons (satiety) and inhibits NPY/AgRP neurons (suppressing hunger), resulting in an anorexigenic effect.     * PYY: Inhibits NPY/AgRP neurons, suppressing hunger.     * Ghrelin: Stimulates NPY/AgRP neurons, increasing appetite (orexigenic effect).

GLP-1 and Pharmacological Interventions

  • Glucagon-like Peptide 1 (GLP-1): A hormone produced by the intestines.     * Function: Levels rise rapidly during a meal (especially those high in fats and carbs). It is a short-term satiety signal that tells the body it is full.     * Distribution: GLP-1 receptors are found in the hippocampus, cortex, hypothalamus, and cerebellum.

  • GLP-1 Receptor Agonists: Drugs that mimic GLP-1.     * Effect on Reward: These receptors are found in the Ventral Tegmental Area (VTA) and Nucleus Accumbens. Activation decreases dopamine release in response to high-reward foods.     * Clinical Impact: Reduces "wanting" or the drive to seek food. Patients report that "cravings for sweets are gone" and they "just aren't thinking about food."

  • Ethical and Practical Issues:     * Cost: These drugs are expensive, costing between $500−$1000/month\$500 - \$1000/month.     * Access: Insurance often does not cover these for weight loss alone.     * Data Gaps: There is limited long-term data, and it is unclear what happens when a patient stops the drug.     * Grey Market: Unapproved or compounded versions of semaglutide are being sold illegally.

Obesity and Eating Disorders

  • The Obesity Epidemic: Our bodies are evolutionary optimized to obtain and store energy. Redundant systems fight against weight loss. Obesity is an epidemic in the United States according to BMI standards.

  • Obesity Treatments:     1. Lifestyle changes (Diet and Exercise).     2. GLP-1 Agonists.     3. Liposuction: Surgical removal of fat tissue.     4. Bariatric procedures: Gastric sleeve or gastric bypass to reduce the stomach's absorptive capacity.

  • Major Eating Disorders:     * Anorexia Nervosa: Characterized by severe restriction of energy intake, intense fear of weight gain, and distorted body image.     * Bulimia Nervosa: Marked by recurrent binge eating episodes followed by a lack of control and compensatory purging behaviors.     * Binge Eating Disorder: Marked by recurrent binge eating episodes without compensatory purging, accompanied by a sense of loss of control.

  • General Treatments for Eating Disorders:     * Family-Based Therapy.     * Cognitive Behavioral Therapy (CBT).     * Nutritional rehabilitation/counseling.     * Medications, such as Selective Serotonin Reuptake Inhibitors (SSRIs).